FindTrial
Sign In

A Clinical Investigation to Assess The Effects of Resveratrol on Circadian and Hypoxia related Gene Regulation in Thalassemia

Nutrigenomic Insights into Thalassemia: Resveratrols Influence on HIF-1a and Clock/BMAL1 Genes Expression, Oxidative Stress and bone mineral density (BMD) of North Indian Thalassemia Patients - NIL

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/12/077531
Enrollment
70
Registered
2024-12-02
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D561- Beta thalassemia

Interventions

Intervention1: Trans Resveratrol 500mg : Trans- Resveratrol (500 mg) Trans-Resveratrol is available as a health supplement in capsule form (500mg) and is approved for human use. It is available from

Sponsors

King Georges Medical University, Lucknow
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with thalassemia major Age above 6 years Willing to provide informed consent

Exclusion criteria

Exclusion criteria: Participants with concomitant hematological disorders other than thalassemia (e.g., sickle cell anemia) are excluded. Individuals who are less than 6 years of age Individuals who are not willing to provide informed consent

Design outcomes

Primary

MeasureTime frame
Change of gene expression, improvement of Bone Mineral Density and Oxidative StressTimepoint: Baseline (0 month) and after intervention (6month)—

Secondary

MeasureTime frame
Not ApplicableTimepoint: Not Applicable—

Countries

India

Contacts

Public ContactNeha Rawat

King Georges Medical University

nitunigam@kgmcindia.edu9411472648

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026